ePrints

How to deal with polarized Th2 cells: exploring the Achilles' heel

Lookup NU author(s): Professor Catharien Hilkens

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

The central effector cells in the pathogenesis of atopic allergic diseases are type 2 T helper (Th2) cells, which display an aberrant cytokine profile dominated by type 2 cytokines. Initial reports from mouse studies indicated that established and committed Th2 cells are stable and unsusceptible to modulation. However, there is a growing awareness that in humans, established effector Th2 cells are more flexible and can be reverted to predominant Th1 phenotypes. In fact, the Th1-driving cytokine interleukin (IL)-12 is the crucial factor in this respect. IL-12 is mainly produced by dendritic cells (DC), which can be primed for high or low IL-12 production, depending on inflammatory and/or microbial signals they encounter during their residence in the peripheral tissues. Accordingly, both the regulation of and the priming for IL-12 production in DC form ideal targets for therapeutic intervention. The development of new therapies for atopic allergy now focuses on local IL-12-promoting substances to target both the development of new Th2 cells and the persistent population of established allergen-specific Th2 cells.

Publication metadata

Author(s): Smits HH, Hilkens CM, Kalinski P, Kapsenberg ML, Wierenga EA

Publication type: Article

Publication status: Published

Journal: International Archives of Allergy and Immunology

Year: 2001

Volume: 126

Issue: 2

Pages: 102-110

Print publication date: 01/10/2001

ISSN (print): 1018-2438

ISSN (electronic): 1423-0097

Publisher: S. Karger AG

URL: http://dx.doi.org/10.1159/000049500

DOI: 10.1159/000049500

Notes: 1018-2438 Journal Article Review Review, Tutorial

Altmetrics

Share